×
About 14,190 results

ALLMedicine™ Lung Adenocarcinoma Center

Research & Reviews  5,479 results

PHOTODYNAMIC THERAPY FOR THE TREATMENT OF CHOROIDAL METASTASES: A Case Series and Meta-...
https://doi.org/10.1097/IAE.0000000000003433
Retina (Philadelphia, Pa.); Nguyen MT, Stacey AW

May 21st, 2022 - To investigate the efficacy and safety of photodynamic therapy (PDT) in the treatment of choroidal metastasis. We conducted a systematic review of all reported cases of choroidal metastases treated with PDT in literature, and included the cases fr...

Prognostic and predictive markers of limited (1-4) brain metastases in patients with lu...
https://doi.org/10.1016/j.wneu.2022.05.036
World Neurosurgery; Xu G, Yang Mm X et. al.

May 20th, 2022 - Owing to the complexities of brain metastases (BM), accurate and reliable prognostic and predictive factors remain critical roadblocks in patients with lung adenocarcinoma (LUAD) BM who undergo stereotactic radiosurgery (SRS). In total, 132 patien...

Integration of bioinformatics analysis and experimental validation identifies plasma ex...
https://doi.org/10.1002/cam4.4788
Cancer Medicine; Wu J, Feng Z et. al.

May 20th, 2022 - The aim of this study was to identify miRNAs in plasma exosomes as noninvasive biomarkers for the early diagnosis of lung adenocarcinoma (LUAD). First, exosomal miRNA profiling of three patients with early LUAD and three patients with benign lung ...

Deconvolution of malignant pleural effusions immune landscape unravels a novel macropha...
https://doi.org/10.1136/jitc-2021-004239
Journal for Immunotherapy of Cancer; Bruschini S, Pallocca M et. al.

May 19th, 2022 - Immune checkpoint inhibitors are still unable to provide clinical benefit to the large majority of non-small cell lung cancer (NSCLC) patients. A deeper characterization of the tumor immune microenvironment (TIME) is expected to shed light on the ...

see more →

Guidelines  1 results

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatmen...
https://doi.org/10.1200/JCO.2017.76.7293
Journal of Clinical Oncology : Official Journal of the Am... Kalemkerian GP, Narula N et. al.

Feb 6th, 2018 - Purpose In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recently updated their recommendations ...

see more →

Clinicaltrials.gov  48 results

Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT03066297

May 5th, 2022 - Background The standard extent of pulmonary resection for non-small cell lung cancer (NSCLC) is still lobectomy. However, recent advances in imaging technology and staging modalities and the widespread use of computed tomography (CT) screening hav...

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-posi...
https://clinicaltrials.gov/ct2/show/NCT04795245

May 4th, 2022 - The primary objective is to confirm Time on Treatment (TOT) related to afatinib treatment as first-line therapy in patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC). The observation in the r...

Shared Decision Making in Patients With Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT05191485

Mar 10th, 2022 - Under the guidance by Ottawa Decision Support Framework (ODSF), International Patient Decision Aid Standards (IPDAS) and FDA guidance for Identify what is important to patients, the investigators use semi-structured interviews qualitative research...

Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS
https://clinicaltrials.gov/ct2/show/NCT05252676

Feb 23rd, 2022 - The pathological lepidic growth pattern was believed to relate to the ground-glass component, whereas invasive adenocarcinoma patterns relate to the solid component. However, the solid components might be fibrosis rather tumor; and previous studie...

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
https://clinicaltrials.gov/ct2/show/NCT04263090

Feb 9th, 2022 - This is an open-label, dose-escalating Phase I study followed by a Phase 2a dose-expansion phase to study the combination of Rigosertib and Nivolumab in metastatic Kirsten rat sarcoma positive (KRAS+) lung adenocarcinoma patients who have progress...

see more →

News  148 results

Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing
https://www.onclive.com/view/lung-cancer-field-targets-immunotherapy-acquired-resistance-and-genomic-testing

Mar 31st, 2022 - To build on the advances that have been made in lung cancer over the past several years, researchers have their sights set on improving the efficacy of immunotherapy with novel approaches, the ability to overcome acquired resistance to targeted th...

Efforts to Target NRG1 Unlock New Pathways for Treatment
https://www.onclive.com/view/efforts-to-target-nrg1-unlock-new-pathways-for-treatment

Mar 1st, 2022 - The advent and implementation of advanced sequencing technologies in clinical practice have aided in the identification of highly active oncogenic gene fusions. RNA sequencing has illuminated the presence of NRG1 fusions, which, though rare, play ...

Distinct Genomic Profile of Lung Cancer in Never Smokers Comes Into Focus
https://www.onclive.com/view/distinct-genomic-profile-of-lung-cancer-in-never-smokers-comes-into-focus

Feb 10th, 2022 - During the past 2 decades, the treatment of patients with lung cancer has undergone a paradigm shift, a transformation fueled by genome sequencing efforts that have revealed oncogenic driver mutations and fostered targeted drug development. Tobac...

Cisplatin-Induced Acute Kidney Injury and Renal Salt Wasting Syndrome
https://www.mdedge.com/fedprac/article/249799/nephrology
Christopher Russo, Lucy Ma, MD et. al.

Dec 10th, 2021 - Cisplatin is a potent antineoplastic agent derived from platinum and commonly used in the treatment of head and neck, bladder, ovarian, and testicular malignancies. 1,2 Approximately 20% of all cancer patients are prescribed platinum-based chemothe.

Enhanced Grasp of Oncogenic Drivers Leads to Expanded Treatment Options in NSCLC
https://www.onclive.com/view/enhanced-grasp-of-oncogenic-drivers-leads-to-expanded-treatment-options-in-nsclc

Nov 9th, 2021 - An increased understanding of the biology of non–small cell lung cancer (NSCLC) has led to a significant increase in therapeutic options for patients, according to Lyudmila A. Bazhenova, MD, a medical oncologist and professor of medicine at the Mo...

see more →